Kuru Karabas Munire, Ayhan Mediha, Guney Engin, Serter Mukadder, Meteoglu Ibrahim
Department of Internal Medicine, Manisa Government Hospital, 45000 Manisa, Turkey.
ISRN Endocrinol. 2013 May 9;2013:858690. doi: 10.1155/2013/858690. Print 2013.
Objective. Diabetic nephropathy is the most commonly seen cause of chronic renal failure, and oxidative stress is important in etiology. In the present study, favorable effects (if any) of the treatment with a thiazolidinedione group drug, pioglitazone, on antioxidant enzyme levels in the renal tissue, renal histopathology, and inflammatory cytokine levels have been investigated. Method. Forty male Wistar rats were divided into 4 groups as the control, diabetic control, and 10 and 30 mg pioglitazone-administered diabetic groups. After 4 weeks, antioxidant enzyme levels in renal tissues and inflammatory markers were investigated. Results. Blood glucose levels did not differ between the diabetic control and drug-administered groups. In pioglitazone-administered rats, histopathological findings such as tubular dilation, necrotic tubular epithelium, glomerular focal necrosis, and vascular consolidation were observed at a lesser extent than the diabetic control group. Any difference was not detected between the diabetic groups with respect to the levels of malondialdehyde, superoxide dismutase, catalase, glutathione, nitric oxide, interleukin-6, and tumor necrosis factor-alpha. Conclusion. Pioglitazone regressed development of histopathological lesions such as glomerular focal necrosis, tubular epithelial necrosis, tubular dilation, and vascular wall consolidation. However, any favorable effect on antioxidant enzyme levels in renal tissues and inflammation markers was not detected.
目的。糖尿病肾病是慢性肾衰竭最常见的病因,氧化应激在其病因中起重要作用。在本研究中,已调查了噻唑烷二酮类药物吡格列酮治疗对肾组织抗氧化酶水平、肾脏组织病理学及炎性细胞因子水平的有益作用(若有的话)。方法。将40只雄性Wistar大鼠分为4组,即对照组、糖尿病对照组以及给予10毫克和30毫克吡格列酮的糖尿病组。4周后,对肾组织中的抗氧化酶水平和炎性标志物进行检测。结果。糖尿病对照组与给药组之间的血糖水平无差异。在给予吡格列酮的大鼠中,与糖尿病对照组相比,观察到肾小管扩张、肾小管上皮坏死、肾小球局灶性坏死和血管硬化等组织病理学表现的程度较轻。糖尿病组之间在丙二醛、超氧化物歧化酶、过氧化氢酶、谷胱甘肽、一氧化氮、白细胞介素-6和肿瘤坏死因子-α水平方面未检测到差异。结论。吡格列酮可使肾小球局灶性坏死、肾小管上皮坏死、肾小管扩张和血管壁硬化等组织病理学病变的发展得到缓解。然而,未检测到其对肾组织抗氧化酶水平和炎症标志物有任何有益作用。